Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge represents HealthCap and Wilson Therapeutics AB in private placement
Mandate

Vinge represents HealthCap and Wilson Therapeutics AB in private placement

May 22, 2014

Wilson Therapeutics AB has completed a private placement of USD 40,000,000 (SEK 260,000,000) directed to the venture capital firms Abingworth LLP and MVM Life Science Partners LLP and the existing investor HealthCap.

Wilson Therapeutics AB is a life science company focused on the development of drugs for the treatment of Wilson’s Disease, a rare genetic disease that affects approximately 1 in 15,000 people worldwide. The private placement is conducted to finance further product development, clinical trials and commercialisation of the company’s products.

Vinge represented HealthCap and Wilson Therapeutics AB in the private placement and Vinge’s team consisted of partner Jesper Ottergren together with, among others, Kristian Ford and Karin Engström.

Related

Vinge advises Setra Trävaror in conjunction with the sale of Malå Såg to HS Timber

 The Austrian company HS Timber Group has entered into an agreement to acquire 100 per cent of the shares in the Swedish wood processing company Malå Såg AB from Setra Trävaror AB, a subsidiary of Setra Group AB. The transaction remains subject to approval from the relevant public authorities.
October 29, 2025

Vinge has advised Advania on the acquisition of Visuell Teknik

 Advania has acquired Visuell Teknik, a Swedish provider of audiovisual and meeting technology solutions.
October 28, 2025

Vinge has advised Acrinova in connection with voluntary share redemption offering

 Vinge has advised Acrinova AB (publ) in connection with its voluntary share redemption offering. The offer comprised approximately one-third of the shares in Acrinova, and the acceptance rate reached approximately 97.34 percent, representing a redemption value of approximately SEK 367.4 million.
October 27, 2025